Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies COG#: AALL0433

IRB-HSR# 14391
Service: Cancer (Children) | Category: Cancer (Oncology), Pediatrics
Adult Enrollment: No | Minor Enrollment: No
Primary Investigator: Kimberly Dunsmore, M.D.

Contact Information

Contact: Candace Hudspeth
Phone: 434.982.1091
E-mail: ckh3k@virginia.edu

Clinical Trial Description

UVA Health System, Department of Pediatrics seeks: children, adolescents, women and men with B precursor acute lymphoblastic leukemia (ALL) that has come back (relapsed) and is of intermediate risk for research study. To be eligible for enrollment, the patient must be less than 30 years old at the time of relapse.

There is no generally accepted standard treatment for intermediate risk relapse of ALL at this time. Combination chemotherapy has been the main treatment for children with intermediate risk relapsed ALL. In this study, the treatment will be strengthened by giving higher doses of chemotherapy drugs more often. The major goal of this study is to establish an effective therapy and to offer bone marrow transplant to those patients having family matched donors.

All of the chemotherapy drugs given in this study have been used before to treat children with relapsed leukemia. In this study, the experimental treatment will involve giving some drugs at higher doses or more often than they have been given in previous studies; treatment with radiation will be eliminated or given in lower doses and there will be no spinal irradiation. The other treatments will be the same as non-study treatment. The number of study visits and length of visits are comparable to the non-study treatment. The total length of treatment will be 2-2.5 years. Data will be collected for study purposes for 5 years after treatment is completed.

You and/or your insurance will be billed for all study related medication, tests, treatment, and procedures.

Compensation

No compensation is provided for this study.